RedHill Biopharma (RDHL) Announces New USPTO Patent Covering Talicia Through 2034
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
March 11, 2024 7:00 AM EDTU.S. Patent and Trademark Office (USPTO) issues new patent covering Talicia1Â as an all-in-one treatment of Helicobacter pylori (H. pylori), supporting Talicia protection until February 12, 2034
This new patent adds to the existing strong intellectual property portfolio protecting Talicia, including composition of matter and other patents and FDA-granted data exclusivities granted under the GAIN QIDP designation and section 505(b)(2)
Talicia is the only FDA-approved rifabutin-containing all-in-one therapy for the eradication of H.... More
